Benralizumab 100 mg vs placebo
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 100 mg leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (high certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyRate ratio 0.63 [0.49, 0.81]2 studies · 1512 participantsHigh